ANTHEMBiotechnology
Anthem Biosciences Limited — Cash Flow Statement
₹681.45
+5.12%
Anthem Biosciences Limited Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Free Cash Flow | 103.67 Cr | -157.03 Cr | 111.44 Cr | 172.18 Cr |
| Repurchase Of Capital Stock | 0.00 | -148.95 Cr | 0.00 | 0.00 |
| Capital Expenditure | -314.67 Cr | -297.19 Cr | -194.55 Cr | -160.73 Cr |
| End Cash Position | 316.98 Cr | 184.36 Cr | 342.85 Cr | 348.90 Cr |
| Beginning Cash Position | 184.36 Cr | 342.85 Cr | 348.90 Cr | 40.77 Cr |
| Changes In Cash | 132.62 Cr | -158.49 Cr | -6.06 Cr | 308.14 Cr |
| Financing Cash Flow | -133.60 Cr | -77.18 Cr | 63.97 Cr | 180.68 Cr |
| Net Other Financing Charges | -0.12 Cr | -26.15 Cr | -18.91 Cr | 7.78 Cr |
| Interest Paid Cff | -9.67 Cr | -9.54 Cr | -6.68 Cr | -10.09 Cr |
| Preferred Stock Dividend Paid | 0.00 | 0.00 | 0.00 | -10000.00 |
| Net Common Stock Issuance | 0.00 | -148.95 Cr | 0.00 | 247.50 Cr |
| Common Stock Payments | 0.00 | -148.95 Cr | 0.00 | 0.00 |
| Net Issuance Payments Of Debt | -123.81 Cr | 107.46 Cr | 89.57 Cr | -64.52 Cr |
| Net Short Term Debt Issuance | -58.94 Cr | 91.99 Cr | -0.72 Cr | -50.70 Cr |
| Net Long Term Debt Issuance | -64.87 Cr | 15.47 Cr | 90.29 Cr | -13.82 Cr |
| Investing Cash Flow | -152.11 Cr | -221.46 Cr | -376.02 Cr | -205.45 Cr |
| Net Other Investing Changes | -10000.00 | 10000.00 | — | 10000.00 |
| Interest Received Cfi | 64.70 Cr | 40.86 Cr | 29.10 Cr | 9.58 Cr |
| Dividends Received Cfi | 7.48 Cr | 7.03 Cr | 14.87 Cr | 9.38 Cr |
| Net Investment Purchase And Sale | 38.55 Cr | 27.41 Cr | -226.20 Cr | -63.71 Cr |
| Sale Of Investment | 38.55 Cr | 27.41 Cr | — | — |
| Net Intangibles Purchase And Sale | -0.14 Cr | -0.85 Cr | -5.62 Cr | -3.14 Cr |
| Purchase Of Intangibles | -0.14 Cr | -0.85 Cr | -5.62 Cr | -3.14 Cr |
| Net PPE Purchase And Sale | -264.44 Cr | -295.64 Cr | -188.16 Cr | -157.54 Cr |
| Sale Of PPE | 50.09 Cr | 0.69 Cr | 0.77 Cr | 0.06 Cr |
| Purchase Of PPE | -314.53 Cr | -296.33 Cr | -188.93 Cr | -157.59 Cr |
| Operating Cash Flow | 418.34 Cr | 140.15 Cr | 305.99 Cr | 332.91 Cr |
| Taxes Refund Paid | -159.00 Cr | -120.00 Cr | -115.00 Cr | -123.00 Cr |
| Change In Working Capital | -152.37 Cr | -262.00 Cr | -103.63 Cr | -138.90 Cr |
| Change In Other Current Liabilities | 13.63 Cr | 47.76 Cr | -74.32 Cr | -18.39 Cr |
| Change In Other Current Assets | -76.79 Cr | -40.25 Cr | -17.35 Cr | -13.74 Cr |
| Change In Payable | 9.38 Cr | 28.80 Cr | 7.10 Cr | -12.08 Cr |
| Change In Inventory | -129.09 Cr | -81.93 Cr | -71.19 Cr | -23.17 Cr |
| Change In Receivables | 33.05 Cr | -216.38 Cr | 52.13 Cr | -71.53 Cr |
| Other Non Cash Items | -54.37 Cr | -31.33 Cr | -22.41 Cr | 0.51 Cr |
| Stock Based Compensation | 34.35 Cr | 0.00 | 0.00 | — |
| Provisionand Write Offof Assets | 2.02 Cr | 0.00 | 0.00 | — |
| Depreciation And Amortization | 89.37 Cr | 81.82 Cr | 63.77 Cr | 57.84 Cr |
| Amortization Cash Flow | 2.51 Cr | 3.70 Cr | 3.43 Cr | 2.66 Cr |
| Depreciation | 86.86 Cr | 78.12 Cr | 60.35 Cr | 55.18 Cr |
| Pension And Employee Benefit Expense | 1.52 Cr | 0.94 Cr | 0.89 Cr | -0.46 Cr |
| Gain Loss On Investment Securities | -7.04 Cr | -6.61 Cr | -14.93 Cr | -9.21 Cr |
| Net Foreign Currency Exchange Gain Loss | 6.99 Cr | 0.00 | 0.00 | — |
| Net Income From Continuing Operations | 656.87 Cr | 477.32 Cr | 497.30 Cr | 546.14 Cr |
| Issuance Of Debt | — | 107.46 Cr | 90.29 Cr | — |
| Issuance Of Capital Stock | — | 0.00 | 0.00 | 247.50 Cr |
| Common Stock Issuance | — | 0.00 | 0.00 | 247.50 Cr |
| Short Term Debt Issuance | — | 91.99 Cr | — | — |
| Long Term Debt Issuance | — | 15.47 Cr | 90.29 Cr | — |
| Repayment Of Debt | — | — | -0.72 Cr | -64.52 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | 10000.00 | — |
| Short Term Debt Payments | — | — | -0.72 Cr | -50.70 Cr |
| Purchase Of Investment | — | — | -226.20 Cr | -63.71 Cr |
| Cash Dividends Paid | — | — | — | -10000.00 |
| Long Term Debt Payments | — | — | — | -13.82 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Anthem Biosciences Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.